Return to study ST000168 main page
MB Sample ID: SA009326
| Local Sample ID: | ms1862-9 |
| Subject ID: | SU000187 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU000187 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Species Group: | Human |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| ms1862-9 | SA009326 | FL002164 | Placebo | Drug |
| ms1862-9 | SA009326 | FL002164 | Pre | Pre vs. Post |
Collection:
| Collection ID: | CO000174 |
| Collection Summary: | we drew arterialized-venous blood samples into plasma EDTA tubes, processed, and stored them at ? 80?C until analysis. |
| Sample Type: | Blood |
Treatment:
| Treatment ID: | TR000194 |
| Treatment Summary: | Placebo|Metformin |
| Treatment Protocol Comments: | We previously reported the overall study design for the parent study [29]. The current report primarily examines the effect of three months of insulin sensitizer therapy on plasma concentrations of BCAA, AAA, and AA metabolites in overweight/obese adults with fasting hyperglycemia, defined as either impaired fasting glucose or untreated diabetes [29]. Briefly, 25 drug naïve, Northern European American participants with fasting blood glucose concentrations of 108180 mg/dL were randomized to receive either 45 mg of pioglitazone per day plus 1 g of metformin twice per day (n = 12) or placebo (n = 13) for 12 weeks. We chose metformin based on its proven effect on hepatic insulin sensitivity and pioglitazone based on its effect on peripheral insulin sensitivity. Current use of hypoglycemic medications excluded participants from the present study.|We previously reported the overall study design for the parent study [29]. The current report primarily examines the effect of three months of insulin sensitizer therapy on plasma concentrations of BCAA, AAA, and AA metabolites in overweight/obese adults with fasting hyperglycemia, defined as either impaired fasting glucose or untreated diabetes [29]. Briefly, 25 drug naïve, Northern European American participants with fasting blood glucose concentrations of 108180 mg/dL were randomized to receive either 45 mg of pioglitazone per day plus 1 g of metformin twice per day (n = 12) or placebo (n = 13) for 12 weeks. We chose metformin based on its proven effect on hepatic insulin sensitivity and pioglitazone based on its effect on peripheral insulin sensitivity. Current use of hypoglycemic medications excluded participants from the present study. |
Sample Preparation:
| Sampleprep ID: | SP000188 |
| Sampleprep Summary: | Storage of plasma/serum samples at ? 80?C for qualitative and quantitative metabolomics using mass spectrometry are routinely done, demonstrating little to no evidence of storage related decay including samples stored greater than 20 years [7] and [33]. The frozen samples were thawed on ice and spiked with C13-labeled internal standards and processed for analysis as previously described [32]. |
Combined analysis:
| Analysis ID | AN000262 |
|---|---|
| Analysis type | MS |
| Chromatography type | |
| Chromatography system | Waters Acquity |
| Column | |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | Thermo Quantum Ultra |
| Ion Mode | POSITIVE |
| Units | uM |
Chromatography:
| Chromatography ID: | CH000185 |
| Chromatography Summary: | Amino acids in particular are relatively stable for several years, with the exception of their keto-acids (e.g., KIC), which we have not included in the present analysis. Subsequently, we separated the samples using an Acquity UPLC system, followed by mass detection using a TSQ Ultra Quantum from Thermo Finnigan running in ESI positive mode as previously described [32]. We calculated the AA and AA metabolites concentrations using 10 point standard curves as previously described [32]. We handled the pre- and post-intervention samples similarly and analyzed them in the same run. The reproducibility of the UPLC/MS/MS method in the MCRMC is excellent (average CV ~ 9.5%) [32]. |
| Instrument Name: | Waters Acquity |
MS:
| MS ID: | MS000211 |
| Analysis ID: | AN000262 |
| Instrument Name: | Thermo Quantum Ultra |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| Ion Mode: | POSITIVE |
